Over the past 30 years, life expectancy for cancer patients has increased by almost one year (on average) due to new cancer medications.
This is one of many facts about cancer and medicines included in a recently released value paper on oncology medicines. The paper is part of a series designed to position Pfizer as a leader on the issue of the value of medicines among key target audiences – policymakers and policy influencers, patient advocacy organizations, and the media – and drive home the message that pharmaceutical innovations provide incredible value. With topics covering many disease areas, the value papers detail the societal and economic value of medicines and rely on published articles, patient stories, and infographics to illustrate the impact that medicines have had on public health and the economy.
“We’ve taken the most compelling points from a vast body of research and crafted straightforward arguments for the real world,” said Karen Boykin-Towns, Vice President, Worldwide Policy, the group that developed the papers. "Policymakers, patient advocates, and the media don’t have time for complex reams of data. They want credible information in easy-to-digest format, and we’ve achieved this through strong collaboration with the business units, outcomes research, and communications.”
Read the Value of Oncology Medicines and other disease-area focused papers here.